Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 0.90 |
| ▸ | ITPR2 | Q14571 | 4/20 | 0.90 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.90 |
| ▸ | INPP5A | Q14642 | 3/20 | 0.90 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.89 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.80 |
| ▸ | AKT1 | P31749 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29165997 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL9872231 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL4754501 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL1149378 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL15762968 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL12871334 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL5003539 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL12858863 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL113868 | 0.97 | ITPR3 (0.89) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL14396732 | 0.97 | ITPR3 (0.89) | ITPR3ITPR2ITPR1INPP5ASMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151930-A1 | PI3K INHIBITORS AND METHODS OF MAKING AND USING THE SAME | RELAY THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4399196-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4370124-A1 | PI3Ka INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024086664-A2 | COVALENT INHIBITORS OF WILD-TYPE AND MUTANT PI3K AND METHOD OF USES THEREOF | TOTUS MEDICINES INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240066034-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240043390-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-08 | — | — | US | disclosed |
| WO-2024026391-A1 | DIFFERENTIATION OF STEM CELLS IN SUSPENSION CULTURE | UMOJA BIOPHARMA, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20240016808-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2024-01-18 | — | — | US | disclosed |
| US-20230405011-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2023-12-21 | — | — | US | disclosed |
| WO-2023240248-A2 | COMPOSITIONS AND METHODS FOR NK CELL DIFFERENTIATION | UMOJA BIOPHARMA, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| EP-1383916-A4 | TRAC1: MODULATORS OF LYMPHOCYTE ACTIVATION | RIGEL PHARMACEUTICALS INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1412745-A4 | EDG : MODULATORS OF LYMPHOCYTE ACTIVATION AND MIGRATION | RIGEL PHARMACEUTICALS INC (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1412745-A2 | EDG : MODULATORS OF LYMPHOCYTE ACTIVATION AND MIGRATION | Rigel Pharmaceuticals, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-1383916-A2 | TRAC1: MODULATORS OF LYMPHOCYTE ACTIVATION | Rigel Pharmaceuticals, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002085290-A2 | EDG : MODULATORS OF LYMPHOCYTE ACTIVATION AND MIGRATION | RIGEL PHARMACEUTICALS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002081730-A2 | TRAC1: MODULATORS OF LYMPHOCYTE ACTIVATION | RIGEL PHARMACEUTICALS, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405011-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MTOR, CDK4, MAPKAP1 | ITPR3 2990/4885ITPR2 2681/4885ITPR1 2983/4885 |
| US-20240016808-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MTOR, CDK4, MAPKAP1 | ITPR3 2990/4885ITPR2 2681/4885ITPR1 2983/4885 |
| US-20240043390-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | ITPR3 4486/4885ITPR2 4531/4885ITPR1 4378/4885 |
| US-20240066034-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MTOR, CDK4, MAPKAP1 | ITPR3 2990/4885ITPR2 2681/4885ITPR1 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.